| First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ J Niu, C Maurice-Dror, DH Lee, DW Kim, A Nagrial, M Voskoboynik, ... Annals of Oncology 33 (2), 169-180, 2022 | 142 | 2022 |
| LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. C Gomez-Roca, E Yanez, SA Im, E Castanon Alvarez, H Senellart, ... Journal of Clinical Oncology 39 (3_suppl), 94-94, 2021 | 63 | 2021 |
| A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with … MR Patel, TM Bauer, A Jimeno, D Wang, P LoRusso, KT Do, SM Stemmer, ... Journal of Clinical Oncology 38 (15_suppl), 3092-3092, 2020 | 55 | 2020 |
| Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study. L Villanueva, Z Lwin, HC Chung, C Gomez-Roca, F Longo, E Yanez, ... Journal of Clinical Oncology 39 (3_suppl), 321-321, 2021 | 49 | 2021 |
| Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients With Advanced Refractory Solid Tumors. A Muik, E Garralda, I Altintas, F Gieseke, R Geva, E Ben-Ami, ... Cancer Discovery, 2022 | 47 | 2022 |
| First-in-class anti-immunoglobulin–like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors LL Siu, D Wang, J Hilton, R Geva, D Rasco, R Perets, AK Abraham, ... Clinical Cancer Research 28 (1), 57-70, 2022 | 37 | 2022 |
| 1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC MJ Ahn, J Niu, DW Kim, D Rasco, KF Mileham, HC Chung, ... Annals of Oncology 31, S887, 2020 | 36 | 2020 |
| 1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC J Niu, A Nagrial, M Voskoboynik, HC Chung, DH Lee, MJ Ahn, TM Bauer, ... Annals of Oncology 31, S891-S892, 2020 | 24 | 2020 |
| Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. L Villanueva, Z Lwin, HCC Chung, CA Gomez-Roca, F Longo, E Yanez, ... Journal of Clinical Oncology 39 (15_suppl), 4080-4080, 2021 | 23 | 2021 |
| Glucocorticoids as an adjunct to oncologic treatment in solid malignancies–not an innocent bystander C Maurice-Dror, R Perets, G Bar-Sela Critical reviews in oncology/hematology 126, 37-44, 2018 | 23 | 2018 |
| The 5-hydroxymethylcytosine landscape of prostate cancer M Sjöström, SG Zhao, S Levy, M Zhang, Y Ning, R Shrestha, A Lundberg, ... Cancer Research 82 (21), 3888-3902, 2022 | 22 | 2022 |
| A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic … C Maurice-Dror, R Le Moigne, U Vaishampayan, RB Montgomery, ... Investigational New Drugs, 1-8, 2022 | 22 | 2022 |
| LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort. CA Gomez-Roca, E Yanez, SA Im, E Castanon Alvarez, H Senellart, ... Journal of Clinical Oncology 39 (15_suppl), 3564-3564, 2021 | 17 | 2021 |
| Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously … BC Cho, K Yoh, R Perets, A Nagrial, DR Spigel, M Gutierrez, DW Kim, ... Lung Cancer 159, 162-170, 2021 | 13 | 2021 |
| First-in-human phase I/IIa trial to evaluate the safety and initial clinical activity of DuoBody®-PD-L1× 4–1BB (GEN1046) in patients with advanced solid tumors E Garralda, R Geva, E Ben-Ami, C Maurice-Dror, E Calvo, P LoRusso, ... BMJ, 2020 | 13 | 2020 |
| Next‐generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage—Multicenter experience A Moore, Y Bar, C Maurice‐Dror, I Ospovat, M Sarfaty, Y Korzets, ... Head & neck 42 (4), 599-607, 2020 | 12 | 2020 |
| Histologic RNFL thickness in glaucomatous versus normal human eyes C Maurice, Y Friedman, MJ Cohen, E Kaliner, M Mimouni, M Kogan, ... Journal of glaucoma 25 (5), 447-451, 2016 | 12 | 2016 |
| LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors-Results from the gastric cancer cohort HC Chung, Z Lwin, C Gomez-Roca, F Longo, E Yanez, EC Alvarez, ... | 11 | 2021 |
| Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). C Maurice-Dror, N Fonseca, C Herberts, W Fan, AW Wyatt, KN Chi Journal of Clinical Oncology 39 (15_suppl), 5049-5049, 2021 | 9 | 2021 |
| Preclinical characterization and phase I trial results of a bispecific antibody targeting PD-L1 and 4-1BB (GEN1046) in patients with advanced refractory solid tumors. Cancer … A Muik, E Garralda, I Altintas, F Gieseke, R Geva, E Ben-Ami, ... CD-21-1345.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 9 | |
